Fludarabine Phosphate (Fludara) + Rituximab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Low-Grade
Conditions
Lymphoma, Low-Grade
Trial Timeline
Dec 1, 2005 → Jul 1, 2007
NCT ID
NCT00311129About Fludarabine Phosphate (Fludara) + Rituximab
Fludarabine Phosphate (Fludara) + Rituximab is a phase 2 stage product being developed by Sanofi for Lymphoma, Low-Grade. The current trial status is completed. This product is registered under clinical trial identifier NCT00311129. Target conditions include Lymphoma, Low-Grade.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, Low-Grade were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00311129 | Phase 2 | Completed |
Competing Products
20 competing products in Lymphoma, Low-Grade